You are here: Industry Insights > oncology drugs

News List

The New NRDL Becomes Official: Many New Oncology Drugs Are Listed and Some Immune Drugs Become Affordable PharmaSources/Xiaobin
January 07, 2021
The National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2020) (“NRDL”) of China was released by the NHSA and Ministry of Human Resources and Social Security of China.
A Comparison of Top Ten Best-Selling Oncology Drugs in China and the U.S. in 2019 PharmaSources/Caicai
December 24, 2020
Information on the top ten best-selling oncology drugs in China and the U.S. in 2019 has recently been released by a related consulting agency of the industry.
Pharmaceutical News of the Week | CPhI.CN - Policies PharmaSources/Caicai
August 06, 2020
The National Health Commission of China issued the Administrative Measures for the Clinical Use of Oncology Drugs (Draft for Comment) on July 29 in order to strengthen the administration of the clinical use of medical institutions’ oncology drugs.
Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and world market PharmaSources/Xiaobin
July 03, 2020
The first half of 2020 will pass soon. Although foreign countries are still under the shadow of the COVID-19 pandemic, China’s situation is gradually stabilizing and improving through the concerted efforts of all to fight the pandemic.
A Review of the Anticancer Drugs Approved in China in 2019 PharmaSources/Yefenghong
February 06, 2020
A review of the 7 blockbuster innovative oncology drugs approved by the NMPA (National Medical Products Administration of China) in 2019.
Sales of generic oncology drugs surge europeanpharmaceuticalreview
February 21, 2019
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028…
Acrotech Biopharma to buy seven drugs from Spectrum for $300m pharmaceutical-technology
January 21, 2019
Aurobindo Pharma USA subsidiary Acrotech Biopharma has signed a definitive agreement to buy seven haematology and oncology drugs from Spectrum Pharmaceuticals for a consideration of up to $300m.....
Anaeropharma, Chugai come together to create Novel Oncology Drugs biospectrumasia
October 23, 2018
Under the agreement, Anaeropharma and Chugai conduct joint research regarding specific oncology substances by use of Anaeropharma's i-DPS technology and Chugai's technology
Novartis hands over global rights for two oncology drugs to Shanghai's Laekna pharmafile
August 03, 2018
Novartis has revealed that it has jettisoned two of its clinical stage oncology products along with exclusive global development and commercialisation rights to Shanghai-based biotech firm Laekna.
AstraZeneca's oncology drugs receive regulatory boost biospectrumasia
April 08, 2018
US FDA has granted priority review for its AstraZeneca's candidate that treats leukemia while EU has accepted the Marketing Authorisation Application ) for Lynparza

Previous page 1 2 Next page